Finally, there is preclinical evidence to demonstrate the tumourigenic impact of PIK3CA/TP53 mutated cancers [36,37,38], and that this subset of breast cancers has a worse clinical prognosis [35]. The gene discussed is TP53; the disease is breast cancer.